Another mechanism contributing to the development of adaptive resistance to anti-PD-1 immunotherapy is the activation of the tumor-intrinsic NOD-, LRR- and pyrin domain-containing protein-3 (NLRP3) inflammasome–heat shock protein 70 (HSP70) signaling axis. The gene discussed is NLRP3; the disease is neoplasm.